DeveloGen AG is a biopharmaceutical company engaged in the discovery and development of novel therapeutics for the treatment of metabolic and endocrine diseases. The company has a highly innovative and deep preclinical discovery pipeline addressing the key drivers in the development of diabetes and obesity such as insulin resistance and loss of insulin-producing beta cells. This pipeline includes programs for the potential treatment of obesity through orally available small molecules based on novel and proprietary targets as well as growth factors targeting beta cell regeneration (type 1 and type 2 diabetes). DeveloGen is based in Göttingen, Germany. For more information on DeveloGen, please visit www.develogen.com.
DeveloGen is part of the Evotec group
Forschung & Lehre